Global Alliance marks sixth Myotonic Dystrophy Awareness Day

More than 60 organizations are marking the sixth International Myotonic Dystrophy Awareness Day on Sept. 15, 2026, to push earlier diagnosis, stronger patient registries, better care and more research for people living with myotonic dystrophy. The campaign underscores how under-recognized the inherited disease remains and how global coordination is shaping clinical progress.

Why it matters: - Myotonic dystrophy is a progressive inherited disease that can affect muscles, the heart, lungs, endocrine system, gastrointestinal system and cognition. - The disease may affect as many as 1 in 2,100 people, but diagnosis is often delayed for years after symptoms begin. - Greater awareness can support earlier diagnosis, better care and more opportunities for clinical research and future treatment. - More than 60 organizations are using International Myotonic Dystrophy Awareness Day to strengthen advocacy, registries and access to care for patients and families.

What happened: - The Global Alliance for Myotonic Dystrophy Awareness marked the sixth annual International Myotonic Dystrophy Awareness Day on Sept. 15, 2026. - The alliance said groups around the world are uniting to raise awareness, advance research and improve quality of life for people living with myotonic dystrophy. - The campaign is centered on education, research participation and access to comprehensive care. - The Global Alliance was established in 2021 and now includes more than 60 international nonprofit and charitable organizations, academic and research institutions, biotechnology and pharmaceutical companies, patient advocacy groups and others.

The details: - The alliance’s three shared priorities are improving education and awareness among healthcare professionals, preparing people with myotonic dystrophy to join clinical research and trials, and expanding access to comprehensive care and future treatments. - High-quality patient registries help researchers understand the natural history of myotonic dystrophy, identify potential participants for clinical studies and reflect patient experiences in therapy development. - Dr. Gisela Nogales, principal investigator of DM1-Hub in Spain, said cross-border collaboration and robust patient registries are laying the foundation for breakthrough research, better clinical care and improved outcomes. - Researchers, clinicians, industry partners and patient organizations are working together worldwide to better understand the disease and evaluate potential therapies. - The article says an increasing number of clinical studies and investigational programs are underway. - Dr. Mike Snape, CEO of AMO Pharma, said recent scientific advice from FDA, Health Canada and MHRA on how to move forward with another clinical study is an exciting milestone for AMO Pharma and the broader community. - The Global Alliance says access to knowledgeable healthcare professionals, reliable information, support services and community connections can make a meaningful difference from diagnosis through care. - Alan Breathnach, CEO of Muscular Dystrophy Ireland, said no family should have to navigate myotonic dystrophy alone and that awareness can lead to earlier diagnosis and better care.

Between the lines: - The campaign reflects a shift from awareness alone to infrastructure-building, especially through registries and research readiness. - The repeated focus on collaboration suggests the field is trying to overcome the fragmentation that often slows progress in rare diseases. - The emphasis on earlier diagnosis also signals a practical goal: connect patients to care and trials sooner, before symptoms and complications advance.

What's next: - The Global Alliance is urging people to mark Sept. 15 by wearing green, sharing stories, posting educational resources, contacting elected officials, requesting green landmark lighting and raising awareness locally. - The group says every conversation and act of advocacy moves the community closer to timely diagnosis, comprehensive care and effective treatments. - The alliance’s long-term goal is to change the future of myotonic dystrophy through continued international cooperation.